Clarity Pharmaceuticals
Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that provide high accuracy and precision in cancer treatment.
Short position
Clarity Pharmaceuticals (ASX:CU6) has 8.94% of its shares on issue reported as short positions as of 5 Oct 2026, or about 33,345,512 shares. Over the past 30 days that figure has risen 0.39 percentage points, and over 90 days it has risen 1.63 percentage points. Its highest recorded short interest was 10.24% in July 2025. CU6 is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Clarity Pharmaceuticals (CU6) short interest history
CU6 Short Interest History
- 30-day change
- +0.39pp
- 90-day change
- +1.63pp
- 1-year change
- +3.17pp
- All-time high
- 10.24% (July 2025)
- All-time low
- 0.00% (April 2023)
Is CU6 heavily shorted?
CU6's short interest of 8.94% is elevated relative to the ASX average, ranking #21 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has CU6's short interest changed recently?
Over the past 30 days Clarity Pharmaceuticals's short interest has been broadly stable, and over 90 days it has risen 1.63 percentage points. The current level is 8.94% of shares on issue.
What is the highest CU6's short interest has been?
Since 2021, Clarity Pharmaceuticals's short interest peaked at 10.24% in July 2025 and bottomed at 0.00% in April 2023.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2021. See our methodology.